These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19661545)

  • 1. Biologic therapies for psoriasis.
    de Felice C; Ardigo M; Berardesca E
    J Rheumatol Suppl; 2009 Aug; 83():62-4. PubMed ID: 19661545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of remission of biologic agents for chronic plaque psoriasis.
    Langley RG; Gordon KB
    J Drugs Dermatol; 2007 Dec; 6(12):1205-12. PubMed ID: 18189060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psoriasis in the era of biologics].
    Torres T; Velho GC; Sanches M; Selores M
    Acta Med Port; 2010; 23(3):493-8. PubMed ID: 20654269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to managing patients with nail psoriasis.
    Reich K
    J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining clinical response in psoriasis: targeting the pathological basis of disease.
    Ortonne JP
    J Drugs Dermatol; 2004; 3(1):13-20. PubMed ID: 14964742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological markers in the etiology of psoriasis: Targeted treatment options.
    de Felice C; Marulli GC; Ardigò M; Berardesca E
    Biologics; 2007 Mar; 1(1):11-8. PubMed ID: 19707344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
    Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
    J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term data in the treatment of psoriasis.
    Thaçi D
    Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing treatment with biologics.
    Mader R; Keystone E
    J Rheumatol Suppl; 2007 Nov; 80():16-24. PubMed ID: 17985419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriatic arthritis management update - biotherapeutic options.
    Saber TP; Veale DJ
    J Rheumatol Suppl; 2009 Aug; 83():65-8. PubMed ID: 19661546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
    Myers WA; Gottlieb AB; Mease P
    Clin Dermatol; 2006; 24(5):438-47. PubMed ID: 16966023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease.
    Marchesoni A; Altomare G; Matucci-Cerinic M; Balato N; Olivieri I; Salvarani C; Lotti T; Scarpa R; Vena GA; Valesini G; Giannetti A
    J Eur Acad Dermatol Venereol; 2010 May; 24(5):578-86. PubMed ID: 19874430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.